Denis Patrick is Vice President, Head of Partnering Innovation and Managing Partner of Pfizer Ventures. Dr. Patrick capitalizes upon his experience in evaluating external opportunities that are focused on areas that complement Pfizer’s Research interests to identify, invest and manage equity investments. He is currently responsible for managing investments in AnTolRx, Encycle, NextCure, eFFECTOR, MISSION Therapeutics, and Metabomed. Dr. Patrick previously engaged in oncology research for several large pharma oncology organizations, including Merck, DuPont Pharma, and GSK. Prior to coming to Pfizer, Dr. Patrick contributed significantly to several oncology drug discovery efforts that led to the approval of three marketed therapeutic agents including nelarabine, trametinib, and dabrafenib. He received his B.S. in Biochemistry from SUNY, a M.S. in Biology from UCSD and a Ph.D. in Biochemistry from the University of Pennsylvania.